<DOC>
	<DOC>NCT02552953</DOC>
	<brief_summary>This is an open-label, single arm, dose escalation study in patients with advanced cancers.</brief_summary>
	<brief_title>A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers</brief_title>
	<detailed_description>This is an open-label, single arm, dose escalation study in patients with advanced cancers. Treatment will be administered on an outpatient basis.</detailed_description>
	<mesh_term>Cyclin-Dependent Kinase Inhibitor Proteins</mesh_term>
	<criteria>Histologically or cytologically confirmed solid tumors or lymphomas that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective 18 years or older ECOG performance status 01 Life expectancy â‰¥ 3 months Evaluable disease Adequate organ functions 4 weeks from prior chemotherapy ( 6 weeks for mitomycin C and nitrosourea) , immunotherapy, investigational anticancer therapy, radiation therapy; and have recovered from prior toxicities At least 4 weeks from major surgery Agree to practice effective contraception Agree to follow protocol required evaluations Ability to understand and willingness to sign the informed consent form Previously untreated CNS metastasis or progressive CNS metastasis Currently receiving radiotherapy, biological therapy, or any other investigational agents Uncontrolled intercurrent illness Pregnant or lactating women Known to be HIVpositive Known active hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>